Zevra Therapeutics (NASDAQ:ZVRA) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS

Zevra Therapeutics (NASDAQ:ZVRA) announced its quarterly earnings results on Wednesday. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12, FiscalAI reports. The firm had revenue of $36.22 million during the quarter, compared to the consensus estimate of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 58.24%.

Here are the key takeaways from Zevra Therapeutics’ conference call:

• Zevra reported strong commercial traction in Q1 with $36.2 million in net revenue (up 78% YoY) and 170 prescription enrollment forms for MIPLYFFA since launch (9 in Q1), representing roughly half of the diagnosed U.S. NPC patient pool and 69% coverage of lives.
• The company monetized non-core assets by selling the SDX portfolio for $50 million, recorded a one-time gain (~$43.3M), received the bulk of proceeds in Q1, paid off debt early (saving ~ $8M/year) and ended March with $236.8 million in cash and no debt.
• Q1 GAAP net income of $37.9 million was driven largely by the SDX sale one-time gain; on an adjusted basis excluding those items net income was ~$11.5 million, and the company has largely exhausted usable NOL carryforwards and recorded a ~$6.9M tax provision.
• The phase III DiSCOVER trial of celiprolol for vEDS has enrolled 62 patients (10 in Q1) and is event‑driven with only 2 of 28 events confirmed for the interim analysis; management is pursuing enrollment initiatives and a follow-up FDA Type C meeting in H2 to explore acceleration options.
• Regulatory and global expansion progress includes an EMA marketing authorization application for arimoclomol (responses to 120‑day questions submitted), orphan designation in Europe, and 122 patients enrolled in the global EAP—supporting potential European commercialization upside.

Zevra Therapeutics Trading Down 2.2%

NASDAQ:ZVRA opened at $11.00 on Friday. The company has a market capitalization of $650.32 million, a P/E ratio of 5.53 and a beta of 0.88. The company has a current ratio of 5.68, a quick ratio of 5.63 and a debt-to-equity ratio of 0.40. Zevra Therapeutics has a 12 month low of $7.16 and a 12 month high of $13.16. The firm has a fifty day simple moving average of $9.73 and a 200-day simple moving average of $9.25.

Zevra Therapeutics News Summary

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q1 results materially beat expectations: Zevra reported $0.18 EPS vs. $0.06 consensus and revenue of $36.2M (vs. ~$32M est.), reflecting 78% revenue growth year-over-year and strong margins. These results and the company’s corporate update signal near-term operational momentum. Zevra Reports First Quarter 2026 Financial Results and Corporate Update
• Positive Sentiment: Balance sheet boost from asset sale: Zevra completed a $50.0M sale of its SDX portfolio to Commave Therapeutics and reported a cash position of ~$236.8M, improving liquidity and optionality for commercialization or M&A. Zevra Reports First Quarter 2026 Financial Results and Corporate Update
• Positive Sentiment: Near-term analyst upgrades: HC Wainwright raised Q2–Q4 2026 EPS estimates (e.g., Q2 to $0.06, Q3 to $0.11, Q4 to $0.17) and increased its FY2030 outlook, suggesting the firm now expects stronger near-term profitability. Zevra Therapeutics (ZVRA) – MarketBeat
• Neutral Sentiment: Full Q1 earnings call and transcripts are available (useful for detail on product performance, margins and management commentary). Investors can review the call for color on sustainability of revenue and commercialization execution. Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Commentary pieces and valuations discussions (e.g., whether share strength already reflects upside) are circulating—useful for weighing risk/reward but not new company facts. Is It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?
• Negative Sentiment: Mixed-to-lower medium-term estimates from HC Wainwright: while near-term quarters were raised, the firm trimmed FY2027–FY2029 and FY2028 notably (e.g., FY2027 cut to $1.06 from $1.16; FY2028 cut to $1.49 from $1.75; FY2029 slightly trimmed), signaling tempered long-term growth visibility that could cap multiple expansion. Zevra Therapeutics (ZVRA) – MarketBeat

Institutional Trading of Zevra Therapeutics

Large investors have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. raised its stake in shares of Zevra Therapeutics by 15.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after purchasing an additional 550,000 shares during the last quarter. Vanguard Group Inc. raised its position in Zevra Therapeutics by 4.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,083,362 shares of the company’s stock worth $29,323,000 after buying an additional 130,676 shares during the last quarter. Nantahala Capital Management LLC boosted its holdings in shares of Zevra Therapeutics by 34.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock valued at $18,753,000 after acquiring an additional 500,000 shares during the last quarter. Rubric Capital Management LP increased its stake in shares of Zevra Therapeutics by 60.8% in the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after acquiring an additional 740,584 shares during the period. Finally, State Street Corp raised its holdings in shares of Zevra Therapeutics by 3.9% during the fourth quarter. State Street Corp now owns 1,482,956 shares of the company’s stock worth $13,287,000 after purchasing an additional 55,665 shares during the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Analyst Upgrades and Downgrades

ZVRA has been the subject of several recent analyst reports. Guggenheim set a $23.00 price objective on shares of Zevra Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, March 10th. BTIG Research assumed coverage on Zevra Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $23.00 target price for the company. Weiss Ratings raised shares of Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research report on Tuesday, March 10th. Finally, Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, April 11th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $23.00.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.